Meyka Pro banner
DURECT Corporation

DURECT Corporation Fundamental Analysis (NASDAQ: DRRX)

DRRX●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$1.91
$0.02(1.04%)
U.S. Market opens in 6h 8m

DURECT Corporation Fundamental Analysis (NASDAQ: DRRX)

DURECT Corporation (NASDAQ: DRRX) shows weak financial fundamentals with a PE ratio of -7.07, profit margin of -4.10%, and ROE of -69.62%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position19.97%
PEG Ratio-0.04
Current Ratio1.71

Areas of Concern

ROE-69.62%
Operating Margin-9.31%
We analyze DRRX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -439.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-439.7/100

We analyze DRRX's fundamental strength across five key dimensions:

Efficiency Score

Weak

DRRX struggles to generate sufficient returns from assets.

ROA > 10%
-45.36%

Valuation Score

Excellent

DRRX trades at attractive valuation levels.

PE < 25
-7.07
PEG Ratio < 2
-0.04

Growth Score

Weak

DRRX faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

DRRX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.24
Current Ratio > 1
1.71

Profitability Score

Weak

DRRX struggles to sustain strong margins.

ROE > 15%
-6961.61%
Net Margin ≥ 15%
-4.10%
Positive Free Cash Flow
No

Key Financial Metrics

Is DRRX Expensive or Cheap?

P/E Ratio

DRRX trades at -7.07 times earnings. This suggests potential undervaluation.

-7.07

PEG Ratio

When adjusting for growth, DRRX's PEG of -0.04 indicates potential undervaluation.

-0.04

Price to Book

The market values DURECT Corporation at 6.47 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.47

EV/EBITDA

Enterprise value stands at -3.62 times EBITDA. This is generally considered low.

-3.62

How Well Does DRRX Make Money?

Net Profit Margin

For every $100 in sales, DURECT Corporation keeps $-4.10 as profit after all expenses.

-4.10%

Operating Margin

Core operations generate -9.31 in profit for every $100 in revenue, before interest and taxes.

-9.31%

ROE

Management delivers $-69.62 in profit for every $100 of shareholder equity.

-69.62%

ROA

DURECT Corporation generates $-45.36 in profit for every $100 in assets, demonstrating efficient asset deployment.

-45.36%

Following the Money - Real Cash Generation

Operating Cash Flow

DURECT Corporation generates limited operating cash flow of $-19.16M, signaling weaker underlying cash strength.

$-19.16M

Free Cash Flow

DURECT Corporation generates weak or negative free cash flow of $-19.16M, restricting financial flexibility.

$-19.16M

FCF Per Share

Each share generates $-0.62 in free cash annually.

$-0.62

FCF Yield

DRRX converts -32.18% of its market value into free cash.

-32.18%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-7.07

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.04

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.47

vs 25 benchmark

P/S Ratio

Price to sales ratio

29.20

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.24

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.71

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.70

vs 25 benchmark

ROA

Return on assets percentage

-0.45

vs 25 benchmark

ROCE

Return on capital employed

-1.78

vs 25 benchmark

How DRRX Stacks Against Its Sector Peers

MetricDRRX ValueSector AveragePerformance
P/E Ratio-7.0731.25 Better (Cheaper)
ROE-69.62%563.00% Weak
Net Margin-409.85%7024.00% Weak
Debt/Equity0.240.51 Strong (Low Leverage)
Current Ratio1.715.76 Neutral
ROA-45.36%-63.00% (disorted) Weak

DRRX outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews DURECT Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ